This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

7 Stocks Rising on Unusual Volume

Stocks in this article: BEXPKMISNDASQNMMSBHALOACHN

Sequenom (SQNM) is a diagnostic testing and genetics analysis company committed to providing products, services, diagnostic testing, applications and genetic analysis products. The stocks is up 34 cents, or 6.4%, at $5.66 in recent trading.

Volume: 4.4 million

Average Volume: 1.5 million

Volume % Change: 187.8%

Ratings: Of 11 analysts covering the stock, seven rate it a buy, three rate it a hold, and one rates it a sell. TheStreet Ratings has a D- sell rating on Sequenom.

Sequenom shows up on a recent list of the 10 Most Shorted Stocks in Biotech and was one of 11 Stocks Loved or Hated by Hedge Funds in the most recently reported quarter.

Mesabi Trust (MSB) is a grantor trust in the U.S. The stocks is up 37 cents, or 1.6%, at $24.16 in recent trading.

Volume: 238,971

Average Volume: 115,800

Volume % Change: 105.8%

Ratings: The single analyst covering Mesabi rates it a moderate buy. TheStreet Ratings has a B- buy rating on the stock.

Mesabi is one of the top-yielding financial services stocks.

Halozyme Therapeutics (HALO) is a biopharmaceutical company, which is dedicated to the development and commercialization of products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets. The stocks is trading up 16 cents, or 2.6%, at $6.25 in recent trading.

Volume: 960,982

Average Volume: 490,200

Volume % Change: 95.2%

Ratings: Of 10 analysts covering the stock, eight rate it a buy, and two rate it a hold. TheStreet Ratings has a D- sell rating on Halozyme.

Achillion Pharmaceuticals (ACHN) is a biopharmaceutical company that focuses on the discovery, development and commercialization of innovative treatments for infectious diseases. The stocks is trading up 8 cents, or 1.4%, at $5.90.

Volume: 1.2 million

Average Volume: 600,300

Volume % Change: 89.27%

Ratings: Of 13 analysts covering the stock, 11 rate it a buy, and two rate it a hold. TheStreet Ratings has an E+ sell rating on Achillion.

Acillion shows up on a recent list of 10 Hep C Stocks on Wall Street's Watch List.

RELATED LINKS:



Follow Stockpickr on Twitter and become a fan on Facebook.

Stockpickr is a wholly owned subsidiary of TheStreet.com.
2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,805.41 +127.51 0.76%
S&P 500 1,964.58 +13.76 0.71%
NASDAQ 4,483.7150 +30.9230 0.69%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs